The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
The global Durvalumab market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Durvalumab is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Durvalumab is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Durvalumab include Medimmune (AstraZeneca). etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Durvalumab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Durvalumab.
Report Scope
The Durvalumab market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Durvalumab market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Durvalumab manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Medimmune (AstraZeneca)
Segment by Type
2.4mL Injection
10mL Injection
Segment by Application
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Durvalumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Durvalumab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Durvalumab market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Durvalumab is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Durvalumab is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Durvalumab include Medimmune (AstraZeneca). etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Durvalumab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Durvalumab.
Report Scope
The Durvalumab market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Durvalumab market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Durvalumab manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Medimmune (AstraZeneca)
Segment by Type
2.4mL Injection
10mL Injection
Segment by Application
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Durvalumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Durvalumab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Durvalumab Market Overview
1.1 Product Overview and Scope of Durvalumab
1.2 Durvalumab Segment by Type
1.2.1 Global Durvalumab Market Value Comparison by Type (2024-2030)
1.2.2 2.4mL Injection
1.2.3 10mL Injection
1.3 Durvalumab Segment by Application
1.3.1 Global Durvalumab Market Value by Application: (2024-2030)
1.3.2 Locally Advanced Urothelial Carcinoma
1.3.3 Metastatic Urothelial Carcinoma
1.3.4 Others
1.4 Global Durvalumab Market Size Estimates and Forecasts
1.4.1 Global Durvalumab Revenue 2019-2030
1.4.2 Global Durvalumab Sales 2019-2030
1.4.3 Global Durvalumab Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Durvalumab Market Competition by Manufacturers
2.1 Global Durvalumab Sales Market Share by Manufacturers (2019-2024)
2.2 Global Durvalumab Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Durvalumab Average Price by Manufacturers (2019-2024)
2.4 Global Durvalumab Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Durvalumab, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Durvalumab, Product Type & Application
2.7 Durvalumab Market Competitive Situation and Trends
2.7.1 Durvalumab Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Durvalumab Players Market Share by Revenue
2.7.3 Global Durvalumab Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Durvalumab Retrospective Market Scenario by Region
3.1 Global Durvalumab Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Durvalumab Global Durvalumab Sales by Region: 2019-2030
3.2.1 Global Durvalumab Sales by Region: 2019-2024
3.2.2 Global Durvalumab Sales by Region: 2025-2030
3.3 Global Durvalumab Global Durvalumab Revenue by Region: 2019-2030
3.3.1 Global Durvalumab Revenue by Region: 2019-2024
3.3.2 Global Durvalumab Revenue by Region: 2025-2030
3.4 North America Durvalumab Market Facts & Figures by Country
3.4.1 North America Durvalumab Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Durvalumab Sales by Country (2019-2030)
3.4.3 North America Durvalumab Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Durvalumab Market Facts & Figures by Country
3.5.1 Europe Durvalumab Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Durvalumab Sales by Country (2019-2030)
3.5.3 Europe Durvalumab Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Durvalumab Market Facts & Figures by Country
3.6.1 Asia Pacific Durvalumab Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Durvalumab Sales by Country (2019-2030)
3.6.3 Asia Pacific Durvalumab Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Durvalumab Market Facts & Figures by Country
3.7.1 Latin America Durvalumab Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Durvalumab Sales by Country (2019-2030)
3.7.3 Latin America Durvalumab Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Durvalumab Market Facts & Figures by Country
3.8.1 Middle East and Africa Durvalumab Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Durvalumab Sales by Country (2019-2030)
3.8.3 Middle East and Africa Durvalumab Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Durvalumab Sales by Type (2019-2030)
4.1.1 Global Durvalumab Sales by Type (2019-2024)
4.1.2 Global Durvalumab Sales by Type (2025-2030)
4.1.3 Global Durvalumab Sales Market Share by Type (2019-2030)
4.2 Global Durvalumab Revenue by Type (2019-2030)
4.2.1 Global Durvalumab Revenue by Type (2019-2024)
4.2.2 Global Durvalumab Revenue by Type (2025-2030)
4.2.3 Global Durvalumab Revenue Market Share by Type (2019-2030)
4.3 Global Durvalumab Price by Type (2019-2030)
5 Segment by Application
5.1 Global Durvalumab Sales by Application (2019-2030)
5.1.1 Global Durvalumab Sales by Application (2019-2024)
5.1.2 Global Durvalumab Sales by Application (2025-2030)
5.1.3 Global Durvalumab Sales Market Share by Application (2019-2030)
5.2 Global Durvalumab Revenue by Application (2019-2030)
5.2.1 Global Durvalumab Revenue by Application (2019-2024)
5.2.2 Global Durvalumab Revenue by Application (2025-2030)
5.2.3 Global Durvalumab Revenue Market Share by Application (2019-2030)
5.3 Global Durvalumab Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Medimmune (AstraZeneca)
6.1.1 Medimmune (AstraZeneca) Corporation Information
6.1.2 Medimmune (AstraZeneca) Description and Business Overview
6.1.3 Medimmune (AstraZeneca) Durvalumab Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Medimmune (AstraZeneca) Durvalumab Product Portfolio
6.1.5 Medimmune (AstraZeneca) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Durvalumab Industry Chain Analysis
7.2 Durvalumab Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Durvalumab Production Mode & Process
7.4 Durvalumab Sales and Marketing
7.4.1 Durvalumab Sales Channels
7.4.2 Durvalumab Distributors
7.5 Durvalumab Customers
8 Durvalumab Market Dynamics
8.1 Durvalumab Industry Trends
8.2 Durvalumab Market Drivers
8.3 Durvalumab Market Challenges
8.4 Durvalumab Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Durvalumab Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Durvalumab Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Durvalumab Market Competitive Situation by Manufacturers in 2023
Table 4. Global Durvalumab Sales (K Pcs) of Key Manufacturers (2019-2024)
Table 5. Global Durvalumab Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Durvalumab Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Durvalumab Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Durvalumab Average Price (USD/Pcs) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Durvalumab, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Durvalumab, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Durvalumab, Product Type & Application
Table 12. Global Key Manufacturers of Durvalumab, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Durvalumab by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Durvalumab as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Durvalumab Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Durvalumab Sales by Region (2019-2024) & (K Pcs)
Table 18. Global Durvalumab Sales Market Share by Region (2019-2024)
Table 19. Global Durvalumab Sales by Region (2025-2030) & (K Pcs)
Table 20. Global Durvalumab Sales Market Share by Region (2025-2030)
Table 21. Global Durvalumab Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Durvalumab Revenue Market Share by Region (2019-2024)
Table 23. Global Durvalumab Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Durvalumab Revenue Market Share by Region (2025-2030)
Table 25. North America Durvalumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Durvalumab Sales by Country (2019-2024) & (K Pcs)
Table 27. North America Durvalumab Sales by Country (2025-2030) & (K Pcs)
Table 28. North America Durvalumab Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Durvalumab Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Durvalumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Durvalumab Sales by Country (2019-2024) & (K Pcs)
Table 32. Europe Durvalumab Sales by Country (2025-2030) & (K Pcs)
Table 33. Europe Durvalumab Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Durvalumab Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Durvalumab Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Durvalumab Sales by Region (2019-2024) & (K Pcs)
Table 37. Asia Pacific Durvalumab Sales by Region (2025-2030) & (K Pcs)
Table 38. Asia Pacific Durvalumab Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Durvalumab Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Durvalumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Durvalumab Sales by Country (2019-2024) & (K Pcs)
Table 42. Latin America Durvalumab Sales by Country (2025-2030) & (K Pcs)
Table 43. Latin America Durvalumab Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Durvalumab Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Durvalumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Durvalumab Sales by Country (2019-2024) & (K Pcs)
Table 47. Middle East & Africa Durvalumab Sales by Country (2025-2030) & (K Pcs)
Table 48. Middle East & Africa Durvalumab Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Durvalumab Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Durvalumab Sales (K Pcs) by Type (2019-2024)
Table 51. Global Durvalumab Sales (K Pcs) by Type (2025-2030)
Table 52. Global Durvalumab Sales Market Share by Type (2019-2024)
Table 53. Global Durvalumab Sales Market Share by Type (2025-2030)
Table 54. Global Durvalumab Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Durvalumab Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Durvalumab Revenue Market Share by Type (2019-2024)
Table 57. Global Durvalumab Revenue Market Share by Type (2025-2030)
Table 58. Global Durvalumab Price (USD/Pcs) by Type (2019-2024)
Table 59. Global Durvalumab Price (USD/Pcs) by Type (2025-2030)
Table 60. Global Durvalumab Sales (K Pcs) by Application (2019-2024)
Table 61. Global Durvalumab Sales (K Pcs) by Application (2025-2030)
Table 62. Global Durvalumab Sales Market Share by Application (2019-2024)
Table 63. Global Durvalumab Sales Market Share by Application (2025-2030)
Table 64. Global Durvalumab Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Durvalumab Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Durvalumab Revenue Market Share by Application (2019-2024)
Table 67. Global Durvalumab Revenue Market Share by Application (2025-2030)
Table 68. Global Durvalumab Price (USD/Pcs) by Application (2019-2024)
Table 69. Global Durvalumab Price (USD/Pcs) by Application (2025-2030)
Table 70. Medimmune (AstraZeneca) Corporation Information
Table 71. Medimmune (AstraZeneca) Description and Business Overview
Table 72. Medimmune (AstraZeneca) Durvalumab Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 73. Medimmune (AstraZeneca) Durvalumab Product
Table 74. Medimmune (AstraZeneca) Recent Developments/Updates
Table 75. Key Raw Materials Lists
Table 76. Raw Materials Key Suppliers Lists
Table 77. Durvalumab Distributors List
Table 78. Durvalumab Customers List
Table 79. Durvalumab Market Trends
Table 80. Durvalumab Market Drivers
Table 81. Durvalumab Market Challenges
Table 82. Durvalumab Market Restraints
Table 83. Research Programs/Design for This Report
Table 84. Key Data Information from Secondary Sources
Table 85. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Durvalumab
Figure 2. Global Durvalumab Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Durvalumab Market Share by Type in 2023 & 2030
Figure 4. 2.4mL Injection Product Picture
Figure 5. 10mL Injection Product Picture
Figure 6. Global Durvalumab Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Durvalumab Market Share by Application in 2023 & 2030
Figure 8. Locally Advanced Urothelial Carcinoma
Figure 9. Metastatic Urothelial Carcinoma
Figure 10. Others
Figure 11. Global Durvalumab Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Durvalumab Market Size (2019-2030) & (US$ Million)
Figure 13. Global Durvalumab Sales (2019-2030) & (K Pcs)
Figure 14. Global Durvalumab Average Price (USD/Pcs) & (2019-2030)
Figure 15. Durvalumab Report Years Considered
Figure 16. Durvalumab Sales Share by Manufacturers in 2023
Figure 17. Global Durvalumab Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Durvalumab Players: Market Share by Revenue in 2023
Figure 19. Durvalumab Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Durvalumab Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Durvalumab Sales Market Share by Country (2019-2030)
Figure 22. North America Durvalumab Revenue Market Share by Country (2019-2030)
Figure 23. U.S. Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Durvalumab Sales Market Share by Country (2019-2030)
Figure 26. Europe Durvalumab Revenue Market Share by Country (2019-2030)
Figure 27. Germany Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Durvalumab Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Durvalumab Revenue Market Share by Region (2019-2030)
Figure 34. China Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Taiwan Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Indonesia Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Thailand Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Malaysia Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Philippines Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Latin America Durvalumab Sales Market Share by Country (2019-2030)
Figure 45. Latin America Durvalumab Revenue Market Share by Country (2019-2030)
Figure 46. Mexico Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Durvalumab Sales Market Share by Country (2019-2030)
Figure 50. Middle East & Africa Durvalumab Revenue Market Share by Country (2019-2030)
Figure 51. Turkey Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. U.A.E Durvalumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Global Sales Market Share of Durvalumab by Type (2019-2030)
Figure 55. Global Revenue Market Share of Durvalumab by Type (2019-2030)
Figure 56. Global Durvalumab Price (USD/Pcs) by Type (2019-2030)
Figure 57. Global Sales Market Share of Durvalumab by Application (2019-2030)
Figure 58. Global Revenue Market Share of Durvalumab by Application (2019-2030)
Figure 59. Global Durvalumab Price (USD/Pcs) by Application (2019-2030)
Figure 60. Durvalumab Value Chain
Figure 61. Durvalumab Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
